Jonathan Swerdlin

@jordantcarlisle @vijaypande @function @OpenAI @AnthropicAI Long live Jordan.

@swerdlin @vijaypande @function @OpenAI @AnthropicAI Thank you @swerdlin. Your work is having an impact x.com/jordantcarlisl…

Whoop just launched a $299 blood biomarker panel for women's health. 11 hormonal markers. AI-powered action plans. Respect the move. But notice the pattern: Whoop deepens its own stack instead of integrating across your ecosystem. Your Whoop blood panel doesn't talk to your Oura sleep data. Your CGM glucose patterns don't inform your recovery scores. Your genetics report sits in a PDF nobody reads. Every health tech company is building a deeper silo. Nobody's building the bridge. That bridge — connecting wearables + bloodwork + genetics + your lived experience into one coherent picture — is where the real intelligence emerges. What's your most underused health data source right now?

@vijaypande @jordantcarlisle @function @OpenAI @AnthropicAI Thanks Vijay. We’ve just added Microsoft Copilot and Perplexity in recent days.

@jordantcarlisle @function Recent @function partnerships with @OpenAI and @AnthropicAI are natural conduits, with more to come prnewswire.com/news-releases/…

@jacobandreou @mustafasuleyman @satyanadella @jacobandreou stoked to work with you

Starting a new chapter today and stepping in to bring Consumer and Commercial Copilot together into one org. One team, one product, one experience. Grateful to @mustafasuleyman and @satyanadella for the opportunity. Let's build.

@Lpa_Doc About f’ing time.

@thekaransinghal 💯

Long live @RobinhoodApp

@vijaypande @dr_alphalyrae Sounds familiar

Spot on

@omooretweets @a16z @drbarnard @RevenueCat Amen

Everyone is talking about the death of consumer apps in the vibe coding era. But at @a16z, I see B2C AI startups growing and retaining users better than every before. My takeaways on how consumer founders succeed in the AI era 👇

@RohunJauhar @function has got you.

your weekly reminder to spend $2,000 ASAP to potentially save your life: 1. CCTA + Cleerly 2. Full Body MRI 1 hour and $2k to save your life from avoidable catastrophe

@stephenolmon @RohunJauhar @function has got you Functionhealth.com/scans

@RohunJauhar Where to go? Have to get rec via GP?

@BobTroia @function Bingo

Looks like @function Function Health no longer requires 2 separate visits (spaced about a week apart) at Quest Diagnostics to complete all of the comprehensive panel blood draws?

@CathieDWood @ARKInvest @function agrees.

According to @ARKInvest’s research, the most profound application of #AI will be in health care. Deregulation is accelerating this transformation in healthcare. Check out Tempus’s results, reported today.

@stevenedds @function Yes. I’m the most bias but many will agree.

Is @function health legit? I kinda wanna get my labs done. Is it worth the $365 or is it gonna tell me everything I already know?

Long live Greg. It’s calculated from objective biomarkers reflecting system functioning: • Albumin (liver + protein) • Creatinine (kidney) • Glucose (metabolic health / insulin resistance) • hs-CRP (inflammation) • Lymphocyte % (immunity) • MCV + RDW (red blood cells) • ALP (liver/bone/biliary) It’s like a systems performance score. You can have Lyme and still have strong organ function and metabolic markers. I have friends living in upstate NY with a similar profile. Curious if you did Function’s Lyme antibody testing.

function health tells me I'm 22 seems pretty off seeing i have lyme

@chamath @function DM me?

@swerdlin @function Happy to figure this out…

Everything about cancer sucks. Some of the most difficult decisions in cancer are what to do and when to do it: biopsy, resection, passive monitoring etc. Today, clinicians make irreversible calls like 1) do a biopsy or wait, 2) treat or monitor or 3) remove an organ or monitor, using tests that cannot see the full biology of either the body or the cancer. As a result, doctors often overtreat the wrong patients while missing dangerous cancers in others until it’s too late. Five years ago, a sibling trio of Purdue grads cold emailed me from Indianapolis. Their thesis was simple: the science in cancer detection and treatment isn't the bottleneck. The engineering is. Fix the engineering, and you can change the standard of care of cancer forever. We founded @EarlyIsGood together to do this. Here is our mid-decade update after five years (!) of toil. We’ve made some good progress. 1. The Engineering Unlock: Multiomics Most diagnostics fail because they are looking for a needle in a haystack. The results are modest and create many false positives and false negatives. We developed nanotechnology that amplifies the needle making it simpler for us to figure out what is going on. Our nanotechnology allows us to read DNA, RNA, and Proteins simultaneously from a single sample. We detect Proteins at attomolar sensitivity (1000x ELISA) and RNAs at PCR-level sensitivity all without extraction or amplification. Combining all three provides a full picture because:  - DNA tells you what mutations are present
- RNA tells you what the cancer is doing
- Proteins tell you how the body is responding 2. The Proof: Bladder Cancer  We started here because the standard of care today is barbaric. 800,000 people are under surveillance for bladder cancer, enduring invasive cystoscopies that still miss ~20% of tumors. We are finishing a multisite prospective trial now. Standard of Care (Cystoscopy): invasive, repeated every 3-6 months. Our bladder cancer test (BCDx): 92% sensitivity and 97% specificity from a simple urine sample. Most importantly, we catch the high-grade tumors that the current gold standard misses completely. 3. The Next Mountain to Climb: Prostate Cancer

If you’ve watched a father, brother, or friend get a high PSA result, you know the spiral that follows: months of terror, invasive procedures, and paralyzing uncertainty. 20M+ PSA tests are run annually. Most positives are false alarms, leading to 1M+ unnecessary, painful biopsies. Meanwhile, dangerous cancers are often missed. Current commercial tests hover below 50% specificity. That means for every two men they flag, one is a false alarm. We partnered with the Mayo Clinic to solve this. No blood draws. No rectal exams. Just a simple urine test. We are using the same platform that we validated on bladder cancer to achieve unprecedented specificity without sacrificing sensitivity, effectively separating those who need treatment from those who don't.  We will soon be commercializing both our bladder and prostate cancer tests widely. Follow us @EarlyIsGood if you’d like to help or know when/where these tests are available.

@bhalligan Long live Halligan.

This is a photo of my 5 years ago today. I’m quite sure, life can be short. Live it. Love it.

@DevonFrohne @function In partnership with Dr. Steve Brule.

@function It's Wine right? For your health?

Wait til you get a sip of this. Coming 2/17. Turns out science tastes good.

@tjparker You win.

Ah, Juicero 🫡

@sama Smart.

Peter Steinberger is joining OpenAI to drive the next generation of personal agents. He is a genius with a lot of amazing ideas about the future of very smart agents interacting with each other to do very useful things for people. We expect this will quickly become core to our product offerings. OpenClaw will live in a foundation as an open source project that OpenAI will continue to support. The future is going to be extremely multi-agent and it's important to us to support open source as part of that.